Literature DB >> 15810075

Chromic-P32 phosphate treatment of implanted pancreatic carcinoma: mechanism involved.

Lu Liu1, Guo-Sheng Feng, Hong Gao, Guan-Sheng Tong, Yu Wang, Wen Gao, Ying Huang, Cheng Li.   

Abstract

AIM: To study the effects of chromic-P32 phosphate (32P colloids) interstitial administration in Pc-3 implanted pancreatic carcinoma, and investigate its anticancer mechanism.
METHODS: Ninety-eight tumor bearing nude mice were killed at different time points after the injection of 32P colloids to the tumor core with observed radioactivity. The light microscopy, transmission electron microscopy (TEM) and immuno-histochemistry and flow cytometry were used to study the rates of tumor cell necrosis, proliferating cell nuclear antigen index, the micro vessel density (MVD). The changes of the biological response to the lymphatic transported 32P colloids in the inguinal lymph node (ILN) were dynamically observed, and the percentage of tumor cell apoptosis, and Apo2.7, caspase-3, Bcl-2, Bax-related gene expression were observed too.
RESULTS: The half-life of effective medication is 13 d after injection of 32P colloids to the tumor stroma, in 1-6 groups, the tumor cell necrosis rates were 20%, 45%, 65%, 70%, 95% and 4%, respectively (F = 4.14-105.36, P<0.01). MVD were 38.5+/-4.0, 28.0+/-2.9, 17.0+/-2.9, 8.8+/-1.5, 5.7+/-2.3 and 65.0+/-5.2 (t = 11.9-26.1, P<0.01), respectively. Under TEM fairly differentiated Pc-3 cells were found. Thirty days after medication, tumors were shrunk and dried with scabs detached, and those in control group increased in size prominently with plenty of hypodermic blood vessels. In all animals the ILN were enlarged but in medicated animals they appeared later and smaller than those in control group. The extent of irradiative injury in ILN was positively correlated to the dosage of medication. Typical tumor cell apoptosis could be found under TEM in animals with intra-tumoral injection of low dosed 32P colloids. The peak of apoptosis occurred in 2.96 MBq group and 24 h after irradiation. In the course of irradiation-induced apoptosis, the value of Bcl-2/Bax was down regulated; Apo2.7 and caspase-3 protein expression were prominently increased dose dependently.
CONCLUSION: 32P colloids intra-tumor injection having prominent anticancer effectiveness may reveal the ability of promoting cell differentiation. The low dose 32P colloids may induce human pancreatic carcinoma Pc-3 implanted tumor cell apoptosis; Apo2.7, caspase-3, Bcl-2 and Bax protein participated in regulating the process of irradiation induced cell apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15810075      PMCID: PMC4305778          DOI: 10.3748/wjg.v11.i14.2101

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  15 in total

1.  Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells.

Authors:  J U Lee; R Hosotani; M Wada; R Doi; T Kosiba; K Fujimoto; Y Miyamoto; S Tsuji; S Nakajima; Y Nishimura; M Imamura
Journal:  Eur J Cancer       Date:  1999-09       Impact factor: 9.162

Review 2.  Caspases: enemies within.

Authors:  N A Thornberry; Y Lazebnik
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

3.  A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells.

Authors:  C Zhang; Z Ao; A Seth; S F Schlossman
Journal:  J Immunol       Date:  1996-11-01       Impact factor: 5.422

4.  Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c.

Authors:  D G Kirsch; A Doseff; B N Chau; D S Lim; N C de Souza-Pinto; R Hansford; M B Kastan; Y A Lazebnik; J M Hardwick
Journal:  J Biol Chem       Date:  1999-07-23       Impact factor: 5.157

5.  Selective tumor irradiation by infusional brachytherapy in nonresectable pancreatic cancer: a phase I study.

Authors:  S E Order; J A Siegel; R Principato; L E Zeiger; E Johnson; P Lang; R Lustig; P E Wallner
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-12-01       Impact factor: 7.038

6.  Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.

Authors:  M J Zelefsky; T Hollister; A Raben; S Matthews; K E Wallner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-07-15       Impact factor: 7.038

7.  Toxicology of intrahepatic arterial administration of interventional phosphorus-32 glass microspheres to domestic pigs.

Authors:  L Liu; G Teng; D Zhang; J Song; S He; J Guo; W Fang
Journal:  Chin Med J (Engl)       Date:  1999-07       Impact factor: 2.628

8.  Radiation-induced apoptosis and necrosis in Molt-4 cells: a study of dose-effect relationships and their modification.

Authors:  Y Akagi; K Ito; S Sawada
Journal:  Int J Radiat Biol       Date:  1993-07       Impact factor: 2.694

9.  [Sentinel lymph node biopsy in breast cancer].

Authors:  Kunwei Shen; Lamichhane Nirmal; Qixia Han; Jiong Wu; Jingsong Lu; Jiaxin Zhang; Guangyu Liu; Zhimin Shao; Zhenzhou Shen
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2002-05

10.  Phosphorus-32-chromic phosphate for ovarian cancer: I. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy.

Authors:  R A Pattillo; B D Collier; H Abdel-Dayem; K Ozker; C Wilson; A C Ruckert; K Hamilton
Journal:  J Nucl Med       Date:  1995-01       Impact factor: 10.057

View more
  2 in total

1.  Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol.

Authors:  Shahram Akhlaghpoor; Alireza Aziz-Ahari; Mahasti Amoui; Shahnaz Tolooee; Hossein Poorbeigi; Shahab Sheybani
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

2.  [Experimental study of CT guided ³²P-CP-PLLA microparticle implantation in the treatment of rabbit VX2 lung tumor].

Authors:  Donghui Pan; Min Yang; Yuping Xu; Lizhen Wang; Lu Liu; Peilin Huang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.